Heading focuses on delivering evidence-informed, fast-acting treatments for depression, anxiety, PTSD and related mood disorders — notably ketamine, Spravato® (esketamine), and TMS — within a personalized care plan that is accessible via insurance and supported by telehealth and in-center services.
| Fund Size | N/A USD |
| Stages Focus | N/A |
| Sectors Focus | Healthcare |
| Portfolio Size | 0 companies |
Heading Health positions itself as an outcomes-focused, personalized mental healthcare provider that combines innovative therapeutics, data/technology, and insurance navigation to expand access and optimize real-world results. They emphasize a comprehensive, team-based care model that blends psychiatry, therapy, and novel treatments (ketamine, Spravato®, TMS), uses measurement tools to track outcomes, and adapts treatment plans based on data and patient needs.
Active team contains 0 members (0 partners, 0 founders).